BRAF and melanoma: Therefore, we tried to explore whether ABZ exhibits synergistic effects with the cell cycle inhibitor palbociclib, an FDA-approved specific small-molecule inhibitor of CDK4/6, or Vemurafenib (PLX4032), an FDA-approved BRAF kinase inhibitor (BRAFi) for melanoma patients harboring the constitutively active BRAF-V600E mutation.